NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Soft tissue including heart
Soft tissue including heart · 13,910 new · 5,400 deaths (ACS 2026) · mortality 1.3 per 100k · 5-yr RS 65.7% (SEER)
Mortality 1.3 per 100k (SEER / ACS common-sites). Never an artboard percent.
Lifetime ≈ 0.3% (SEER Stat Facts). 181,366 people living with soft tissue including heart cancer in 2023. Female death rate stays a rate per 100k. No encoded screening interval.
181,366 people living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 63 · at death 68 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence men 4.2 / women 3.0 per 100k · mortality men 1.5 / women 1.1 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among people aged 65–74. Deaths highest among people aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases have not changed significantly (2014–2023). Death rates falling 0.6% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.
Highest new-case rate: Non-Hispanic White men 4.3 per 100k. Highest death rate: Non-Hispanic Black men 1.6 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | 3.9 | 3.1 | 1.2 | 1.0 |
| Non-Hispanic American Indian/Alaska Native | 3.3 | 2.9 | 1.4 | 1.1 |
| Non-Hispanic Asian/Pacific Islander | 3.1 | 2.4 | 1.2 | 0.9 |
| Non-Hispanic Black | 3.9 | 3.4 | 1.6 | 1.5 |
| Non-Hispanic White | 4.3 | 2.9 | 1.5 | 1.1 |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
No USPSTF population-screening recommendation is cited for this stub.
ACS / SEER pin only. Not encoded. Not a screening recommendation.
Surveillance pointer
ACS-soft-tissue-follow 2026 · cited only · ACS after-treatment page names follow-up visits after treatment, which may include exams, lab tests, x-rays, and scans. Those months are not encoded. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Not an imaging surveillance engine.
Named public source only. Not a personal follow-up calendar. ACS-soft-tissue-follow
Surveillance pointer
ACS-soft-tissue-follow 2026 · cited only · ACS after-treatment page names second cancers after soft-tissue sarcoma treatment, including a different soft-tissue sarcoma, bone, stomach, thyroid, melanoma, and AML. Radiation and chemotherapy likely contribute to the leukemia cases. Named later-cancer sites are not encoded. Experts do not recommend any additional testing to look for second cancers in patients without symptoms. Complementary to the living-as pointer. Official lifetime figures are not restated. Female death rate stays a rate per 100k. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-soft-tissue-follow
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names later heart problems after anthracyclines, peripheral neuropathy after chemo, and fertility effects after chemo or radiation to the pelvis, belly, or spine. Those names are not encoded. Complementary to the living-as pointer. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Not a fertility-preservation or neuropathy-score engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names echoes after cardiotoxic chemo and lung function tests after some chemo or a stem-cell or bone-marrow transplant, plus a treatment summary and survivorship care plan. Those named tests and plans are not encoded. Complementary to the sarcoma printout. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
ACS-soft-tissue-follow 2026 · empty on purpose · ACS after-treatment page names late or long-term side effects on the survivorship care plan. Those late effects are not encoded. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-soft-tissue-follow
Toxicity pointer
ACS-soft-tissue-follow 2026 · empty on purpose · ACS after-treatment page names later cancers after soft-tissue sarcoma treatment, including AML. Those second-cancer risks are not encoded. Complementary to the living-as pointer. Official lifetime figures are not restated. Female death rate stays a rate per 100k. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-soft-tissue-follow
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later heart problems after anthracyclines, peripheral neuropathy, and fertility effects after pelvis, belly, or spine radiation. Those late effects are not encoded. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names echoes after cardiotoxic chemo and lung function tests after some chemo or transplant. Those named tests are not encoded. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Complementary to the sarcoma printout. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — Sarcoma
Acute: ACS names fatigue, field dermatitis, hair loss in the field, and pain or swelling. Late: skin and fibrosis change, lymphedema, heart problems after anthracyclines, neuropathy, fertility effects, sexuality changes, lasting fatigue, bowel or bladder problems after abdomen or pelvis treatment, hearing loss after high-dose platinum chemo, and cognitive change after chemo. Monitor: field wound or infection; later heart checks after some sarcoma chemo; echoes after cardiotoxic chemo; lung function tests after some chemo or transplant; lasting fatigue or sleep problems; bowel or bladder change after abdomen or pelvis treatment; hearing change after high-dose platinum chemo; fertility after pelvis, belly, or spine treatment; sexuality or body-image change; memory, thinking, or focus change after chemo. Those names are not encoded. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Not a fracture-risk or second-primary screening engine.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
ACS follow-up tests named here
Echoes after cardiotoxic chemo · Lung function tests after some chemo or a stem-cell or bone-marrow transplant
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Bone and soft-tissue are cited sarcoma algorithm sites. Complementary ACS long-term page is named, not encoded. Official bone and soft-tissue age-band percent-of-cases cells are not restated. Female soft-tissue death rate stays a rate per 100k. No invented trial percent.
Open Sarcoma printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-stub-soft-tissue · stub · none · v2-stub-soft-tissue
SEER 5-year relative survival by stage (cited stub)
Localized 83.3% · Regional 58.2% · Distant 17.0% · All 65.7%
Soft tissue including heart. Female death rate stays a rate per 100k. Official age-band percent-of-cases cells are not restated.
Percent of cases by stage (SEER Stat Facts)
Localized 57% · Regional 18% · Distant 17% · Unknown 8%
Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Soft tissue including heart. Official age-band percent-of-cases cells are not restated.
lifetime
Soft tissue including heart birth-to-death
≈ 0.3%
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
not computed — v2 stubCited ACS/SEER population pin only
screening
No ACS population-screening sentence cited
No ACS can-it-be-found-early sentence is cited. SEER Stat Facts and ACS after-treatment pins only. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
surveillance
ACS follow-up cited — soft-tissue months not encoded
Cited ACS after-treatment page only. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
toxicity
ACS late effects cited — soft-tissue months not encoded
Empty on purpose. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
Noah · Plan — skin cancer
not computed — v2 stubCited ACS/SEER population pin only
screening
No ACS population-screening sentence cited
No ACS can-it-be-found-early sentence is cited. SEER Stat Facts and ACS after-treatment pins only. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
surveillance
ACS follow-up cited — soft-tissue months not encoded
Cited ACS after-treatment page only. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
toxicity
ACS late effects cited — soft-tissue months not encoded
Empty on purpose. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
Walter · S1 prostate
not computed — v2 stubCited ACS/SEER population pin only
screening
No ACS population-screening sentence cited
No ACS can-it-be-found-early sentence is cited. SEER Stat Facts and ACS after-treatment pins only. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
surveillance
ACS follow-up cited — soft-tissue months not encoded
Cited ACS after-treatment page only. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
toxicity
ACS late effects cited — soft-tissue months not encoded
Empty on purpose. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
Priya · average-risk
not computed — v2 stubCited ACS/SEER population pin only
screening
No ACS population-screening sentence cited
No ACS can-it-be-found-early sentence is cited. SEER Stat Facts and ACS after-treatment pins only. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
surveillance
ACS follow-up cited — soft-tissue months not encoded
Cited ACS after-treatment page only. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
toxicity
ACS late effects cited — soft-tissue months not encoded
Empty on purpose. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k.
not encoded
Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.